Analyst Consensus ?
ConsensusHold34 ratings
Bullish1441.2%
Neutral1544.1%
Bearish514.7%
ResMed Inc. · RMD · FY2026 Q2 · Calendar Q1 2026
ResMed: Growth Broadens as Execution Risks Remain
The supplied analysis supports a constructive but conditional view: resilient demand, product expansion, digital-health tools, and operating leverage can sustain growth, but the case depends on disciplined execution and manageable competitive, regulatory, and integration risks.
Reported After market closeNYSEHealthcare
$32.07B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.81
Consensus $2.74
EPS surprise
+2.6%
Reported versus consensus
Reported revenue
$1.42B
Consensus $1.40B
Revenue surprise
+1.6%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+0.3%
Event window
SPY move
-0.3%
Same window
Abnormal move
+0.6%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
-0.4%
Up to 20 sessions
RMDSPY benchmark
Ask FN2 about RMD FY2026 Q2
Transcript, numbers and history already loaded
Why did RMD rise 0.3% after beating EPS estimates in FY2026 Q2?What changed in RMD's guidance and outlook in FY2026 Q2?Give me the bull and bear case for RMD after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior analysis, the current analysis places greater emphasis on the F30i portfolio, FDA-cleared Comfort Match, capacity expansion, and the potential contribution of GLP-1-related patient acquisition. The overall tone remains confident, while concerns around SG&A, acquisitions, Philips, regulation, currency, and supply remain present.
Guidance delta
Maintained; the analysis does not identify a change in guidance sentiment.
Key takeaways
- The current analysis describes continued growth led by masks and accessories, alongside device growth.
- Margin expansion remains an important part of the operating narrative.
- F30i masks and Comfort Match extend the product and digital-health roadmap.
- The patient funnel is being supported by education, partnerships, and GLP-1-related demand.
- The growth case still depends on execution across products, capacity, acquisitions, and competition.
Management priorities
- Expand the F30i Comfort and Clear mask portfolio, subject to regulatory approvals.
- Scale Comfort Match across the device portfolio.
- Expand U.S. distribution and manufacturing capacity.
- Continue tuck-in acquisitions and partnerships in digital sleep health.
- Support patient acquisition through education and ecosystem initiatives.
Follow RMD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$223.02Current
$175Low
$248.69Average
$345High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Outperform | Sector Perform | Upgrade | Sep 15, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 31, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| Citigroup | Neutral | Buy | Downgrade | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Jun 17, 2026 |
| Stifel | Hold | Hold | Maintain | Jan 30, 2026 |
| Baird | Neutral | Outperform | Downgrade | Dec 16, 2025 |
| UBS | Buy | Buy | Maintain | Aug 1, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Apr 24, 2025 |
| Needham | Hold | Hold | Maintain | Jan 31, 2025 |
| B of A Securities | Buy | Buy | Maintain | Sep 26, 2024 |
| Wolfe Research | Underperform | Peer Perform | Downgrade | Sep 18, 2024 |
| Oppenheimer | Perform | Outperform | Downgrade | Jun 25, 2024 |
| CLSA | Buy | Outperform | Maintain | Jan 13, 2022 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 6, 2021 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jul 29, 2019 |
| Deutsche Bank | Buy | Hold | Upgrade | Mar 20, 2019 |
| BMO Capital | Outperform | Market Perform | Upgrade | Dec 10, 2018 |
| Barclays | Underweight | Underweight | Maintain | Oct 27, 2017 |
| Credit Suisse | Neutral | Outperform | Downgrade | Aug 2, 2017 |
| Bank of America | Neutral | Buy | Downgrade | Aug 2, 2017 |
| PiperJaffray | Neutral | Overweight | Downgrade | Apr 27, 2016 |
| BBY | Underperform | Underperform | Maintain | Feb 2, 2015 |
| Northland Securities | Underperform | Market Perform | Downgrade | May 27, 2014 |
| Northland Capital Markets | Underperform | Market Perform | Downgrade | May 27, 2014 |
| William Blair | Market Perform | Outperform | Downgrade | Jan 24, 2014 |
| Shaw Stockbroking | Buy | Buy | Maintain | Sep 20, 2013 |
| S&P Capital IQ | Buy | Buy | Maintain | Feb 26, 2013 |
| CBA | Buy | Hold | Upgrade | Aug 7, 2012 |
| Feltl & Co. | Hold | Hold | Maintain | Aug 6, 2012 |
| Bank oferica | Neutral | Neutral | Maintain | Apr 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $223.02. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Craig Wong-Pan | $262 | $222.99 | +17.5% | Sep 15, 2026 |
| KeyBanc | Analyst unavailable | $267 | $240.33 | +19.7% | Aug 31, 2026 |
| Redburn Partners | Analyst unavailable | $230 | $219.98 | +3.1% | Aug 19, 2026 |
| Robert W. Baird | Analyst unavailable | $213 | $212.38 | -4.5% | Aug 7, 2026 |
| KeyBanc | Analyst unavailable | $255 | $223.24 | +14.3% | Aug 7, 2026 |
| UBS | David Low | $300 | $195.97 | +34.5% | Jul 21, 2026 |
| RBC Capital | Analyst unavailable | $234 | $198.57 | +4.9% | Jul 16, 2026 |
| Mizuho Securities | Analyst unavailable | $220 | $193.01 | -1.4% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $225 | $204.5 | +0.9% | Jul 10, 2026 |
| RBC Capital | Analyst unavailable | $276 | $219.75 | +23.8% | Jul 8, 2026 |
| Wells Fargo | Analyst unavailable | $225 | $219.75 | +0.9% | Jul 8, 2026 |
| KeyBanc | Analyst unavailable | $266 | $188.63 | +19.3% | Jun 22, 2026 |
| Morgan Stanley | David Bailey | $230 | $193.94 | +3.1% | Jun 17, 2026 |
| Robert W. Baird | Analyst unavailable | $225 | $203.87 | +0.9% | May 1, 2026 |
| KeyBanc | Analyst unavailable | $290 | $219.85 | +30.0% | Apr 27, 2026 |
| Evercore ISI | Anthony Petrone | $255 | $228.33 | +14.3% | Apr 13, 2026 |
| RBC Capital | Craig Wong-Pan | $314 | $254.08 | +40.8% | Jan 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $265 | $257.61 | +18.8% | Jan 30, 2026 |
| KeyBanc | Brett Fishbin | $302 | $257.61 | +35.4% | Jan 30, 2026 |
| Robert W. Baird | Analyst unavailable | $281 | $257.61 | +26.0% | Jan 30, 2026 |
| Piper Sandler | Analyst unavailable | $275 | $257.61 | +23.3% | Jan 30, 2026 |
| Stifel Nicolaus | Jonathan Block | $260 | $245.94 | +16.6% | Dec 18, 2025 |
| Robert W. Baird | Analyst unavailable | $275 | $253.07 | +23.3% | Dec 16, 2025 |
| UBS | Marcus Curley | $345 | $251.38 | +54.7% | Dec 12, 2025 |
| Robert W. Baird | Analyst unavailable | $300 | $246.88 | +34.5% | Nov 3, 2025 |
| KeyBanc | Brett Fishbin | $299 | $244.12 | +34.1% | Oct 31, 2025 |
| Morgan Stanley | David Bailey | $305 | $252.26 | +36.8% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $304 | $271.41 | +36.3% | Oct 21, 2025 |
| Wells Fargo | Analyst unavailable | $280 | $272 | +25.5% | Oct 13, 2025 |
| Morgan Stanley | David Bailey | $286 | $248.14 | +28.2% | May 20, 2025 |
| KeyBanc | Brett Fishbin | $274 | $232.65 | +22.9% | Apr 24, 2025 |
| Mizuho Securities | Anthony Petrone | $265 | $211.49 | +18.8% | Apr 16, 2025 |
| Stifel Nicolaus | Analyst unavailable | $240 | $223.83 | +7.6% | Mar 5, 2025 |
| Piper Sandler | Adam Maeder | $260 | $236.18 | +16.6% | Jan 31, 2025 |
| Stifel Nicolaus | Jonathan Block | $250 | $242.51 | +12.1% | Dec 12, 2024 |
| RBC Capital | Craig Wong-Pan | $224 | $238.95 | +0.4% | Oct 1, 2024 |
| Robert W. Baird | Joe Vruwink | $280 | $246.18 | +25.5% | Sep 23, 2024 |
| Wolfe Research | Mike Polark | $180 | $250.88 | -19.3% | Sep 18, 2024 |
| RBC Capital | Craig Wong-Pan | $187 | $194.27 | -16.2% | Apr 10, 2024 |
| Stifel Nicolaus | Mike Matson | $224 | $198.03 | +0.4% | Apr 1, 2024 |
| Oppenheimer | Suraj Kalia | $175 | $134.65 | -21.5% | Oct 27, 2023 |
| Needham | Mike Matson | $180 | $153.89 | -19.3% | Sep 6, 2023 |
| RBC Capital | Craig Wong-Pan | $244 | $197.57 | +9.4% | Jun 20, 2022 |
| RBC Capital | Analyst unavailable | $233 | $200.81 | +4.5% | Apr 29, 2022 |
| Oppenheimer | Suraj Kalia | $312 | $253.77 | +39.9% | Oct 14, 2021 |
| Morgan Stanley | Sean Laaman | $250 | $271.87 | +12.1% | Aug 4, 2021 |
| Jefferies | Anthony Petrone | $240 | $264.75 | +7.6% | Jul 28, 2021 |
Track every rating change on RMD the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency.…
Historical context
All RMD earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
- MUFY2026 Q4 · September 30, 2026+5.4% EPS+0.0% move
- CCLFY2026 Q3 · September 29, 2026+5.9% EPS+13.4% move
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
Get the RMD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-01T16:06:10.865368+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-01T16:06:10.862524+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-01. For educational purposes only; not investment advice.